Nitric oxide in streptozotocin-induced diabetes mellitus in rats
- PMID: 8665775
- DOI: 10.1042/cs0900379
Nitric oxide in streptozotocin-induced diabetes mellitus in rats
Abstract
1. The present study was performed to determine the relationship between diabetic glomerular hyperfiltration and nitric oxide as modulated by the chronic administration of L-arginine and/or N-omega-nitro-L-arginine, a known nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats. 2. Normal rats and rats drinking hypertonic glucose (10%) were used as time-controlled groups. Six weeks after administration of streptozotocin the diabetic rats had significantly higher creatinine clearance (667 +/- 53 microliters min-1 100 g-1 body weight) than before and streptozotocin (456 +/- 38 microliters min-1 100 g-1 body weight, P < 0.005) and very high plasma (37.8 +/- 10.9 mumol/l) and urinary (3.492 +/- 0.179 nmol min-1 100 g-1 body weight) nitrite+nitrate (stable metabolites of nitric oxide) values compared with before streptozotocin administration [19.3 +/- 2.8 mumol/l (P < 0.001) and 0.420 +/- 0.051 nmol min-1 100 g-1 body weight (P < 0.001) respectively]. The 6-week diabetic rats had higher systolic blood pressure (124.2 +/- 2.9 mmHg, P < 0.05) than before streptozotocin (108 +/- 8 mmHg), but had a value similar to that of the hypertonic-glucose-drinking rats. 3. The diabetic rats supplemented with L-arginine did not show an increase in creatinine clearance and had a lower urinary excretion of nitrite+nitrate (0.999 +/- 0.27 nmol min-1 100 g-1 body weight, P < 0.005) than the respective untreated streptozotocin-induced diabetic rats. Creatinine clearance increased in the normal and glucose-drinking rats that received L-arginine. The administration of L-arginine resulted in significant reduction in blood pressure in all groups studied. The chronic nitric oxide synthase inhibitor resulted in high blood pressure, and in a significant decrease in creatinine clearance and urinary nitrite+nitrate excretion in all groups studied. In both diabetic and glucose-drinking rats, the L-arginine therapy resulted in significantly lower plasma and urinary glucose levels than in their respective untreated control groups. 4. The nitric oxide synthase inhibitor increased the plasma and urinary glucose concentration in both diabetic and glucose-drinking rats. 5. Our results indicate that diabetic rats are characterized by high plasma concentrations and elevated urinary excretion of nitrite+nitrate, suggesting a state of high nitric oxide production. The vascular response to nitric oxide in diabetic rats may be different at the glomerular and peripheral vascular bed.
Similar articles
-
Nitric oxide in ischaemic acute renal failure of streptozotocin diabetic rats.Diabetologia. 1996 Sep;39(9):1036-40. doi: 10.1007/BF00400651. Diabetologia. 1996. PMID: 8877286
-
Glomerular basement membrane anionic sites in adriamycin nephropathy: effect of saline loading and nitric oxide modulation.Nephron. 2000 Apr;84(4):354-61. doi: 10.1159/000045611. Nephron. 2000. PMID: 10754413
-
Role of nitric oxide in renal function in rats with short and prolonged periods of streptozotocin-induced diabetes.Diabetes Obes Metab. 1999 Nov;1(6):339-46. doi: 10.1046/j.1463-1326.1999.00061.x. Diabetes Obes Metab. 1999. PMID: 11225650
-
Isotopic investigation of nitric oxide metabolism in disease.Curr Opin Clin Nutr Metab Care. 2003 Jan;6(1):103-8. doi: 10.1097/00075197-200301000-00015. Curr Opin Clin Nutr Metab Care. 2003. PMID: 12496687 Review.
-
L-arginine as a therapeutic tool in kidney disease.Semin Nephrol. 2004 Jul;24(4):389-94. doi: 10.1016/j.semnephrol.2004.04.010. Semin Nephrol. 2004. PMID: 15252778 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous